Balyasny Asset Management
VKTX icon

Balyasny Asset Management’s Viking Therapeutics VKTX Stock Holding History

Balyasny Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Buy
+36,493
New +$1.17M ﹤0.01% 2011
2025
Q2 		– Sell
-1,648,628
Closed -$43.4M – 3395
2025
Q1 		$39.8M Buy
1,648,628
+788,179
+92% +$24.9M 0.07% 365
2024
Q4 		$34.6M Buy
+860,449
New +$49.1M 0.05% 444
2024
Q3 		– Sell
-185,382
Closed -$10.9M – 3194
2024
Q2 		$9.83M Buy
185,382
+76,787
+71% +$5.03M 0.02% 900
2024
Q1 		$8.9M Sell
108,595
-2,134,928
-95% -$95M 0.02% 984
2023
Q4 		$41.8M Buy
2,243,523
+121,624
+6% +$1.59M 0.08% 316
2023
Q3 		$23.5M Buy
2,121,899
+1,506,631
+245% +$21.5M 0.05% 520
2023
Q2 		$9.97M Buy
615,268
+58,661
+11% +$1.23M 0.02% 782
2023
Q1 		$9.27M Buy
556,607
+452,837
+436% +$4.68M 0.02% 811
2022
Q4 		$975K Sell
103,770
-2,569,794
-96% -$11.5M ﹤0.01% 1676
2022
Q3 		$7.27M Buy
2,673,564
+30,613
+1% +$100K 0.02% 831
2022
Q2 		$7.64M Buy
+2,642,951
New +$6.54M 0.02% 749
2020
Q3 		– Sell
-10,410
Closed -$75K – 1628
2020
Q2 		$75K Buy
+10,410
New +$69.1K ﹤0.01% 1066
2019
Q4 		– Sell
-10,245
Closed -$70K – 1513
2019
Q3 		$70K Sell
10,245
-8,233
-45% -$61.1K ﹤0.01% 1104
2019
Q2 		$153K Sell
18,478
-43,180
-70% -$369K ﹤0.01% 1411
2019
Q1 		$613K Sell
61,658
-301,948
-83% -$2.53M ﹤0.01% 1152
2018
Q4 		$2.78M Sell
363,606
-731,245
-67% -$8.74M 0.02% 633
2018
Q3 		$19.1M Buy
1,094,851
+839,851
+329% +$9.99M 0.09% 313
2018
Q2 		$2.42M Buy
+255,000
New +$1.7M 0.01% 870

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Balyasny Asset Management's VKTX Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 36,493 shares worth $1.19M. The stake represents ﹤0.01% of the portfolio and ranks #2011 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in VKTX as recently as Q1 2025.

Balyasny Asset Management first reported a position in VKTX in Q2 2018 and has held it in 19 quarters since. The position peaked at $41.8M in Q4 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Balyasny Asset Management held 36,493 shares of Viking Therapeutics worth $1.19M as of Q1 2026.
  • Viking Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Viking Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2011 holding.
  • Balyasny Asset Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 19 quarters since.
  • Balyasny Asset Management's Viking Therapeutics position peaked at $41.8M in Q4 2023.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.